Edwards Lifesciences stock gets FDA approval for AUTUS valve

{
  "signal_id": "f06dc1b2-0f07-aa38-f058-bb7ba741a4eb",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-10-04T19:37:34+00:00",
  "company": {
    "name": "Edwards Lifesciences",
    "domain": "edwards.com"
  },
  "data": {
    "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/edwards-lifesciences-stock-gets-fda-approval-for-autus-valve/70228052",
    "title": "Edwards Lifesciences stock gets FDA approval for AUTUS valve - AD HOC NEWS",
    "excerpt": "Edwards Lifesciences stock (ISIN US28176E1082) closed at USD 85.15 on the NYSE on October 2, 2026, down 0.05 percent from USD 85.19. The company received FDA approval for its AUTUS pediatric pulmonary valve on October 1, 2026, a product event that expands its structural heart portfolio. According to Edwards Lifesciences on October 1, 2026, the FDA approved AUTUS as a surgical pulmonary valve for pediatric patients with congenital heart disease. The valve can be expanded through a minimally invasive transcatheter procedure as a child grows. The pivotal study reported 100 percent of patients free from device-related complications through 30 days, while patients will continue to receive follow-up for 10 years. MarketBeat reported that Edwards posted USD 1.74 billion in second-quarter 2026 revenue, up 13.6 percent from the prior-year quarter, while adjusted EPS reached USD 0.78 versus a USD 0.74 consensus estimate. The same report listed third-quarter 2026 adjusted EPS guidance of USD 0.71-0.77 and full-year 2026 guidance of USD 2.95-3.05. That combination puts the AUTUS approval against a business already delivering double-digit quarterly sales growth. MarketBeat said 17 of 23 covering analysts rated the stock Buy, while six recommended Hold, producing a Moderate Buy consensus and an average 12-month target of USD 100.27. Against the October 2 closing price of USD 85.15, that...",
    "summary": "Edwards Lifesciences reported adjusted earnings per share of USD 0.78 for the second quarter of 2026.",
    "planning": false,
    "image_url": "https://mdb.ad-hoc-news.de/bild/bild-2706937_1920_1080.webp",
    "confidence": 0.8,
    "published_at": "2026-10-04T19:37:34Z",
    "article_sentence": "MarketBeat reported that Edwards posted USD 1.74 billion in second-quarter 2026 revenue, up 13.6 percent from the prior-year quarter, while adjusted EPS reached USD 0.78 versus a USD 0.74 consensus estimate."
  }
}

curl https://signals.autobound.ai/v1/signals/f06dc1b2-0f07-aa38-f058-bb7ba741a4eb \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"edwards.com","limit":20}'